Metformin Prevents Endothelial Dysfunction in Endometriosis through Downregulation of ET-1 and Upregulation of eNOS
Authors:
- Ana Filipa MartinsAMAna Filipa Martins
- Ana Catarina NetoANAna Catarina Neto
- Adriana Raquel RodriguesARAdriana Raquel Rodrigues
- Sandra Marisa OliveiraSOSandra Marisa Oliveira
- Cláudia Sousa-MendesCSCláudia Sousa-Mendes
- Adelino Leite-MoreiraALAdelino Leite-Moreira
- Alexandra Maria GouveiaAlexandra Maria Gouveia
- Henrique AlmeidaHenrique Almeida
- Delminda NevesDNDelminda Neves
Open Access
- 1 November 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (11) , 2782
Abstract
This study aimed to evaluate if the treatment with metformin affects the morphologic structure, endothelial function, angiogenesis, inflammation and oxidation-responsive pathways in the heart of mice with surgically induced endometriosis. B6CBA/F1 mice (n = 37) were divided into four groups; Sham (S), Metformin (M), Endometriosis (E) and Metformin/Endometriosis (ME). The cross-sectional area of cardiomyocytes was assessed after Hematoxylin–Eosin staining and fibrosis after Picrosirius-Red staining. ET-1, nitric oxide synthases-iNOS and eNOS, and VEGF and VEGFR-2 were detected by immunofluorescence. Semi-quantification of ET-1, eNOS, VEGF, NF-kB, Ikβα and KEAP-1 was performed by Western blotting. MIR199a, MIR16-1, MIR18a, MIR20a, MIR155, MIR200a, MIR342, MIR24-1 and MIR320a were quantified by Real-Time qPCR. The interaction of endometriosis and metformin effects was assessed by a two-way ANOVA test. Compared with the other groups, M-treated mice presented a higher cross-sectional area of cardiomyocytes. Heart fibrosis increased with endometriosis. Treatment of endometriosis with metformin in the ME group downregulates ET-1 and upregulates eNOS expression comparatively with the E group. However, metformin failed to mitigate NF-kB expression significantly incremented by endometriosis. The expression of MIR199a, MIR16-1 and MIR18a decreased with endometriosis, whereas MIR20a showed an equivalent trend, altogether reducing cardioprotection. In summary, metformin diminished endometriosis-associated endothelial dysfunction but did not mitigate the increase in NF-kB expression and cardiac fibrosis in mice with endometriosis.Keywords
This publication has 59 references indexed in Scilit:
- How to calculate sample size in animal studies?Journal of Pharmacology and Pharmacotherapeutics, 2013
- Metformin improves healthspan and lifespan in miceNature Communications, 2013
- Angiogenesis and EndometriosisObstetrics and Gynecology International, 2013
- Metformin as a new therapy for endometriosis, its effects on both clinical picture and cytokines profileMiddle East Fertility Society Journal, 2012
- Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activationActa Pharmacologica Sinica, 2011
- Metformin regresses endometriotic implants in rats by improving implant levels of superoxide dismutase, vascular endothelial growth factor, tissue inhibitor of metalloproteinase-2, and matrix metalloproteinase-9American Journal of Obstetrics and Gynecology, 2010
- MicroRNA-320 Is Involved in the Regulation of Cardiac Ischemia/Reperfusion Injury by Targeting Heat-Shock Protein 20Circulation, 2009
- The importance of endothelin-1 for vascular dysfunction in cardiovascular diseaseCardiovascular Research, 2007
- Role of Angiogenesis in Cardiovascular DiseaseCirculation, 2005
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999